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an-dependent nuclear transport requires a nuclear
pool of RanGTP both for the assembly of export com-
plexes and the disassembly of import complexes.
Accordingly, in order for these processes to proceed, Ran-
dependent nuclear import and export assays in vitro require
the addition of GTP to produce RanGTP. Notably, no ATP
requirement can be detected for these transport processes
in vitro. But in vivo, when cells are depleted of ATP by the
addition of sodium azide and 2-deoxyglucose to block ATP
production by oxidative phosphorylation and glycolysis,
R
 
respectively, Ran-dependent nuclear import and export are
rapidly inhibited. This raised the question of whether there
is an ATP requirement for these nuclear transport pathways
in an intact cell that has remained undetected in vitro.
Here we report that the free (but not total) GTP concentration
rapidly drops to an undetectable level upon ATP depletion as
does the availability of RanGTP. Our conclusion is that the
inhibition of Ran-dependent nuclear transport observed upon
ATP depletion in vivo results from a shortage of RanGTP
rather than the inhibition of some ATP-dependent process.
 
Introduction
 
That carrier-dependent nuclear transport of cargo across the
nuclear pore complex (NPC)* requires energy is well estab-
lished, but how is this energy used? Of the 
 
 
 
30 proteins that
comprise the yeast NPC, none of them resemble an ATPase or
GTPase, making it unlikely that the NPC itself has to hy-
drolyze nucleoside triphosphates (NTPs) to power transport
(Rout et al., 2000). Consistent with this, movement of a carrier
(with or without bound cargo) from one side of the NPC to
the other does not require energy (Kose et al., 1997; Yokoya
et al., 1999; Ribbeck and Gorlich, 2001) and is believed
to occur by repeated binding and release of the carrier to
sequential NPC proteins in a process called “facilitated
diffusion” (for review see Talcott and Moore, 1999). In
contrast, however, the signal-mediated accumulation of import
cargo in the nucleus or export cargo in the cytoplasm does
require energy, and we now know that in many cases, at least
part of the energy requirement can be linked to the small
GTPase Ran (Moore, 1998).
The majority of nuclear carriers belong to the karyopherin-
 
 
 
(Kap-
 
 
 
) superfamily, and the one diagnostic feature of carriers
in this family is that they all bind Ran, but critically only
when Ran is in the GTP- rather than the GDP-bound form
(Nakielny and Dreyfuss, 1999). Nuclear transport com-
plexes containing a Kap-
 
 
 
 carrier use the concentration of
RanGTP, which varies widely between the cytoplasm and
nucleus, as a positional cue to regulate their assembly and
disassembly (Gorlich et al., 1996; Izaurralde et al., 1997).
The concentration of RanGTP is kept low in the cytoplasm
and high inside the nucleus by localizing the Ran GTPase
activating protein (GAP) to the cytoplasm and the Ran guanine
nucleotide exchange factor (GEF) (RCC1) to the nucleus.
Crucially, having bound RanGTP has opposite effects on
import versus export carriers on their ability to simulta-
neously bind cargo (Gorlich et al., 1996). Kap-
 
 
 
 carriers
that function in import will only bind their cargo in the
absence of RanGTP (i.e., in the cytoplasm) and the subse-
quent binding of RanGTP inside the nucleus triggers the
release of cargo. Thus, import of a classical nuclear localization
sequence (cNLS)–containing cargo mediated by Kap-
 
 
 
1
and its adaptor Kap-
 
 
 
 requires both nuclear Ran and GTP,
however, GTP hydrolysis by Ran is not required for entry of
the cargo into the nuclear interior (Schwoebel et al., 1998;
Englmeier et al., 1999). Instead, nuclear RanGTP is required
for the disassembly of an incoming transport complex and
the release of cargo triggered by the interaction of Kap-
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with RanGTP (Kutay et al., 1997b). GTP hydrolysis by Ran
in this import pathway occurs only when the RanGTP–
Kap-
 
 
 
1 complex recycles back through the NPC and
encounters the RanGAP in the cytoplasm. Thus, GTP hy-
drolysis by Ran during Ran-dependent nuclear import is re-
quired for recycling transport carriers after import, rather
than for powering the movement of an import cargo
through the NPC into the nucleus. Export carriers exhibit
the reverse behavior, requiring bound RanGTP to simulta-
neously bind their nuclear export sequence (NES)–contain-
ing cargo with high affinity. Upon contact of the export
complex with the RanGAP in the cytoplasm, RanGTP hy-
drolyzes its bound GTP to become RanGDP. As a result of
this GTP hydrolysis, both RanGDP and cargo are released
by the carrier, terminating export.
In vitro, neither Kap-
 
 
 
1–mediated import of cNLS-con-
taining cargo nor Crm1-mediated export of leucine-rich
NES-containing cargo are inhibited by the addition of a
nonhydrolyzable ATP analogue (Schwoebel et al., 1998; En-
glmeier et al., 1999
 
). 
 
In vivo, however, ATP depletion of
cells by metabolic poisons that block oxidative phosphoryla-
tion and/or glycolysis causes a rapid shutdown of cNLS-
mediated import (Richardson et al., 1988; Shulga et al., 1996).
We wanted to determine by what mechanism ATP deple-
tion inhibits Ran-dependent nuclear transport in vivo, par-
ticularly to determine whether there is an ATP-dependent
step in these transport pathways in vivo that has remained
undetected in vitro. Here we report that the in vivo inhibi-
tion of Ran-dependent nuclear transport observed upon
ATP depletion is likely caused by depletion of cellular
RanGTP resulting from a lack of free GTP, rather than inhi-
bition of an ATP-dependent step required for transport.
 
Results
 
Nuclear transport is inhibited in 2-deoxyglucose/azide- 
but not ribavirin-treated cells
 
Because the metabolisms of adenine and guanine nucleotides
are tightly linked in vivo (Hershfield and Seegmiller, 1976;
Detimary et al., 1997; Kondo et al., 2000), we hypothesized
that a simple explanation for the inhibition of Ran-depen-
dent nuclear import in vivo by ATP depletion might be that
this treatment also results in depletion of GTP, preventing
the generation of RanGTP. To test this hypothesis, the Ran-
dependent nuclear transport capability of cells “ATP de-
pleted” with 2-deoxyglucose and sodium azide was compared
with that of cells “GTP depleted” with ribavirin. Azide inhib-
its the production of ATP by oxidative phosphorylation,
Figure 1. ATP depletion of cells with 
2-deoxyglucose/Na azide inhibits both nuclear 
import and export, whereas GTP depletion with 
ribavirin does not. HeLa cells were incubated in 
gluc
  media (2 h), gluc
  media containing ribavirin 
(2 h), or gluc
  media containing 2-deoxyglucose/
azide (20 min). Cells were injected in the cytoplasm 
(A) with FITC–BSA marker (1.25 mg/ml) and the 
nuclear import reporter TRITC–NLS-BSA (1.3 mg/ml), 
or in the nucleus (B) with the marker and the 
nuclear export reporter TRITC–NES-BSA (4.5 mg/ml). 
After injection, the cells were incubated for an 
additional 30 min in the indicated medium 
followed by fixation and fluorescence microscopy. 
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whereas 2-deoxyglucose inhibits ATP production by glycoly-
sis. Ribavirin is an inhibitor of IMP dehydrogenase (the rate
limiting enzyme in de novo GTP biosynthesis) and ribavirin
treatment is known to decrease intracellular GTP levels
(Finch et al., 1993; Yalowitz and Jayaram, 2000).
After treatment with either ribavirin or 2-deoxyglucose/
azide in gluc
 
 
 
 medium, the labeled import substrate
TRITC–NLS-BSA (containing the NLS of the SV40 T anti-
gen) was injected into the cytoplasm of HeLa cells to monitor
import. In other cells, the labeled export substrate TRITC–
NES-BSA (containing the Rev NES) was injected into the
nucleus to monitor export. As a control, cells were injected
after incubation in gluc
 
 
 
 media. As expected from previous
reports (Richardson et al., 1988; Shulga et al., 1996),
TRITC–NLS-BSA was imported into the nuclei of control
cells, but not imported into the nuclei of cells treated with
2-deoxyglucose/azide (Fig. 1 A). Likewise, nuclear injected
TRITC–NES-BSA was exported from the nuclei of control
cells, but not cells treated with 2-deoxyglucose/azide. Unex-
pectedly, however, treatment with ribavirin to lower GTP
levels affected neither the nuclear import of TRITC–NLS-
BSA nor the export of TRITC–NES-BSA (Fig. 1).
 
Total nucleotide levels in ATP- and GTP-depleted cells
 
To compare the nucleotide levels in cells after these treat-
ments, nucleotides were isolated from control and treated
cells and quantitated by FPLC (Kremmer et al., 1989). We
found that treatment with 2-deoxyglucose/azide in gluc
 
 
 
medium for 1 h decreased total cellular ATP to 
 
 
 
40% of
the level in cells incubated in just gluc
 
 
 
 medium (8.22 vs.
3.27 nmoles/10
 
6
 
 cells; Table I). In trial experiments, when
FCS was omitted from the medium during treatment,
2-deoxyglucose/azide treatment for 1 h resulted in much
lower ATP levels (
 
 
 
10% of normal; unpublished data). We
found however that the cells were in such bad shape after
such severe ATP depletion that they were very difficult to
microinject (unpublished data). We found that addition of
FCS to the medium during treatment made the cells more
amenable to microinjection and did not prevent the inhibi-
tion of nuclear transport by 2-deoxyglucose/azide.
As hypothesized, ATP depletion with 2-deoxyglucose/
azide also caused a decrease in the total GTP content from
2.58 to 1.85 nmoles/10
 
6
 
 cells (72% of control levels). GTP
depletion with ribavirin, however, decreased the GTP con-
tent almost twice as much to 36% of control levels (0.87
nmoles/10
 
6
 
 cells) without significantly affecting the ATP
concentration (8.42 vs. 8.32 nmoles/10
 
6
 
 cells). Yet, as
shown in Fig. 2, these GTP-depleted cells are still transport
competent unlike the ATP-depleted cells, indicating that in-
hibition of nuclear transport in 2-deoxyglucose/azide-treated
cells is not the result of a decrease in the levels of total GTP.
Note that although other cell types can contain higher ATP/
GTP ratios than we found here (Franklin and Twose, 1977;
Lee et al., 1985), our measured ATP/GTP ratios of 3.2–3.5
in control cells are nearly identical to those previously deter-
mined in HeLa cells (Finch et al., 1993).
Ran has a 10-fold higher affinity for GDP than GTP and al-
though the RanGEF drastically increases the rate of nucleotide
loading, it does not affect the relative affinity of Ran for GTP
and GDP (Klebe et al., 1995). Other factors may modulate
Figure 2. The cellular localization of nuclear transport factors 
after 2-deoxyglucose/sodium azide or ribavirin treatment. Cells 
were treated with control gluc
  media for 2 h, gluc
  media containing 
ribavirin for 2 h, or gluc
  media containing 2-deoxyglucose/sodium 
azide for 1 h. The cells were fixed and probed with antibodies 
against the indicated nuclear transport factor, followed by fluorescently 
labeled second antibody. Note that Kap-  accumulates in the nuclei 
of 2-deoxyglucose/azide-treated cells, whereas the distribution of 
the other transport factors remains essentially unchanged.
 
Table I. 
 
Measurement of total nucleotide levels in HeLa cells after various treatments
ATP ADP GTP GDP ATP/ADP GTP/GDP
 
Glucose
 
 
 
 media, 1 h 8.22 
 
 
 
 0.75 0.75 
 
 
 
 0.17 2.58 
 
 
 
 0.23 0.29 
 
 
 
 0.07 11.0 8.9
Glucose
 
 
 
 media, 2 h 8.32 
 
 
 
 0.59 0.69 
 
 
 
 0.05 2.4 
 
 
 
 0.2 0.21 
 
 
 
 0.03 12.1 11.4
Ribavirin, 2 h 8.42 
 
 
 
 0.43 0.69 
 
 
 
 0.01 0.87 
 
 
 
 0.01 0.17 
 
 
 
 0.02 12.2 5.1
2-deoxyglucose 
 
 
 
 sodium azide, 1 h 3.27 
 
 
 
 0.60 0.53 
 
 
 
 0.13 1.85 
 
 
 
 0.29 0.27 
 
 
 
 0.07 6.2 6.9
Values are expressed as nmoles nucleotide/10
 
6
 
 cells. Nucleotides were measured in total cellular extracts by FPLC as described in the Materials and methods.
Each value represents the mean 
 
 
 
 SD of three independent experiments. 
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this process in vivo but, based on our current knowledge, the
ratio of RanGTP versus RanGDP generated in a loading reac-
tion is dependent on the ratio of free GTP to GDP in the im-
mediate environment. Because of this, we then measured the
total GDP (and ADP) levels to determine whether an altered
GTP/GDP ratio rather than the total concentration of GTP
in the 2-deoxyglucose/azide-treated cells might be responsible
for the observed transport inhibition. Treatment with 2-deoxy-
glucose/azide did result in a decrease in the GTP/GDP ratio
from 8.3 to 6.9. However, treatment with ribavirin affected
the GTP/GDP ratio more severely, dropping it to 5.1. Thus,
both the total GTP level and GTP/GDP ratio are lower after
ribavirin treatment than 2-deoxyglucose/azide treatment (Ta-
ble I), and yet ribavirin-treated cells remain transport compe-
tent, whereas 2-deoxyglucose/azide treated cells do not. There-
fore, it is not the decrease in total GTP or the GTP/GDP ratio
after 2-deoxyglucose/azide treatment that is responsible for the
observed nuclear transport inhibition.
The Mono-Q and Source 15Q FPLC columns used here
for the quantitation of nucleotides retain and fractionate all
mono-, di-, and triphosphate nucleotides (Hartwick and
Brown, 1975; Kremmer et al., 1989). After 2-deoxyglucose/
azide treatment, we did not see a corresponding increase in
any of the nucleotides (such as AMP) that might possibly rep-
resent breakdown or interconversion products of ATP (un-
published data). This is consistent with a previous report that
a decrease in cellular ATP stimulated by anoxia correlates with
a rise at time points similar to those observed here in the meta-
bolic breakdown products of ATP, such as adenosine, that are
not retained on our FPLC columns (Grune and Siems, 1993).
 
2-deoxyglucose/azide treatment results in a buildup 
of Kap-
 
 
 
 in the nucleus
 
To explore other possibilities for the 2-deoxyglucose/azide
inhibition of nuclear transport, ribavirin- and 2-deoxyglu-
cose/azide-treated cells were fixed and examined by indi-
rect immunofluorescence microscopy to determine whether
these treatments result in a change in the intracellular local-
ization of proteins required for nuclear transport. We did
not observe any significant changes in the localization of
Ran, the RanGAP, or the RanGEF (RCC1) after either
treatment (Fig. 2). Note that cells treated with 2-deoxyglu-
cose/azide tend to round up somewhat, resulting in a de-
crease in the apparent cytoplasmic volume. This morpholog-
ical change can result in a slightly altered appearance (see for
example the Ran localization) without actually changing the
nucleocytoplasmic distribution of the transport factors (Fig.
2). Kap-
 
 
 
1 in some experiments appeared to slightly con-
centrate in the nucleus after 2-deoxyglucose/azide treatment,
but this change was neither dramatic nor consistent. Kap-
 
 
 
,
in contrast, was found to dramatically shift its localization
exclusively to the nuclei of 2-deoxyglucose/azide-treated
cells. Normally, Kap-
 
 
 
 mainly appears either cytosolic or
bound at the nuclear envelope as can be seen in the ribavi-
rin- and gluc
 
 
 
-treated cells (Fig. 2).
During cNLS-mediated import, Kap-
 
 
 
 crosses the NPC
into the nucleus in a complex with cNLS-containing cargo
and Kap-
 
 
 
1 (Gorlich et al., 1995). Upon contact with
RanGTP in the nucleoplasm, this complex disassembles and
Kap-
 
 
 
 is then recycled back to the cytoplasm by the CAS
(cellular apoptosis susceptibility) protein carrier (Kutay et
al., 1997a). CAS requires bound RanGTP to bind Kap-
 
 
 
with high affinity, thus both the import of Kap-
 
 
 
 com-
plexed with cargo and Kap-
 
 
 
1 and the export of Kap-
 
 
 
 me-
diated by CAS require RanGTP (Melchior et al., 1993;
Moore and Blobel, 1993; Kutay et al., 1997a). Accumula-
tion of both the 
 
Saccharomyces cerevisiae
 
 homologue of Kap-
 
 
 
(Srp1p) and vertebrate Kap-
 
 
 
 in the nucleus has been ob-
served previously in cells predicted to have a low concentra-
tion of nuclear RanGTP. Examples of this are cells expressing
a mutant Ran that cannot be converted to the GTP-bound
form, or when the Ran GEF is inactivated (Koepp et al., 1996;
Tachibana et al., 2000). We wondered therefore whether the
cells upon 2-deoxyglucose/azide treatment might be becom-
ing deficient in RanGTP, thus explaining their transport
defect. Accordingly, we devised a method for directly mea-
suring cellular RanGTP to see how this was affected by
2-deoxyglucose/azide treatment.
 
Measurement of in vivo RanGTP levels
 
The percentage of cellular Ran in the GTP-bound form at
steady-state has never been measured, primarily for technical
Figure 3. NEM treatment of HeLa cellular lysates inhibits both 
RanGEF and RanGAP activity. Cellular lysates were prepared as 
described in the Materials and methods and treated with either ( ) 
10, ( ) 20, ( ) 40, or ( ) 60 mM NEM for the indicated period of 
time, quenched with excess DTT, and measured as follows: 
(A) measurement of RanGEF activity in HeLa cell extracts after NEM 
treatment; (B) measurement of RanGAP activity in HeLa cell extracts 
after NEM treatment. Both RanGAP and GEF activity were measured 
as described in the Materials and methods. 
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reasons. A major problem with measuring the intracellular
concentration of RanGTP is that upon cell lysis and prepara-
tion of a cellular extract, Ran and its GAP and GEF become
mixed together instead of remaining spatially separate. In par-
ticular, the mixing of RanGTP with the RanGAP results in
very (artifactually) low levels of RanGTP that can be immu-
noprecipitated from cellular extracts even when the extracts
are kept cold (Lounsbury et al., 1996). Thus, we needed some
way of inhibiting RanGAP and RanGEF activity in cellular
lysates to accurately measure the amount of RanGTP that was
present in the cells before lysis. In experiments not shown, we
found that the Ran GAP and GEF activities in the cellular ly-
sates as measured with exogenously added Ran were not
altered after 2-deoxyglucose/azide treatment (unpublished
data). This result indicated that 2-deoxyglucose/azide treat-
ment does not affect RanGTP production by altering the ac-
tivity of either of these enzymes by, for example, inhibiting an
ATP-dependent posttranslational modification.
We reported previously that the RanGEF activity of
RCC1 is inhibited by pretreatment of RCC1 with the alky-
lating agent 
 
N
 
-ethylmaleimide (NEM) (Schwoebel et al.,
1998), and here we report that the RanGAP activity is also
inhibited by treatment with NEM. We found that both
RanGAP and RanGEF activities in cellular lysates were in-
hibited by NEM in a time- and dose-dependent fashion
(Fig. 3, A and B). In every case, excess DTT was added after
NEM treatment to quench the activity of NEM before as-
say. Note that despite the NEM sensitivity of the Ran GEF
and GAP activities as shown here, Ran itself is known to be
unaffected by NEM treatment (Moore and Blobel, 1992).
Having in hand a treatment to substantially reduce Ran-
GAP and RanGEF activity in cellular lysates, we used this
NEM treatment in conjunction with a new assay that we de-
vised to measure available RanGTP present in a cellular ly-
sate. This assay utilizes the Ran binding domain (RanBD) of
RanBP1, which only binds RanGTP and not RanGDP
(Beddow et al., 1995). After cell lysis and NEM treatment,
the extract is passed over a desalting column to remove
NEM and DTT. A glutathione-
 
S
 
-transferase (GST) pull-
down is then performed with GST–RanBD, and bound Ran
is determined by immunoblotting with an anti-Ran anti-
body. Because only Ran in the GTP-bound form binds the
RanBD, any Ran isolated in this pulldown must be in the
GTP-bound form. Furthermore, only RanGTP not already
complexed with RanBP1 or any other protein that binds to
this region of RanGTP will be isolated in this pulldown.
Figure 4. Isolation of RanGTP with a RanBD fused to GST. 
(A and B) NEM treatment of cellular lysate allows the recovery of 
RanGTP. Either cellular lysates or a solution of BSA were spiked 
with recombinant Ran loaded with either (A) [ -
32P]GTP or (B) 
[ -
32P]GTP before pulldown of RanGTP with GST–RanBD. The radiolabeled Ran and NEM were added together with 2 mM GDP- S upon 
cell lysis as described in the Materials and methods. Samples were either NEM treated to abolish RanGAP and GEF activity (100 mM NEM for 
20 min) before quenching with 200 mM DTT, or mock treated in which the order of addition of NEM and DTT was reversed. After gel filtration 
to remove excess NEM and DTT, RanGTP was isolated in a pulldown with GST–RanBD and glutathione-agarose. In the indicated samples, 
GST was substituted for the GST–RanBD; these samples were mock treated. Shown are the CPM of radiolabeled Ran associated with the 
GST–RanBD glutathione-agarose beads after washing. (C) No free RanGTP can be detected in HeLa cells treated with 2-deoxyglucose/azide. 
HeLa cells were either untreated (lanes 1 and 6–8), incubated in gluc
  media for either 1 (lane 2) or 2 h (lane 4), incubated with 2-deoxyglucose/
azide in gluc
  media for 1 h (lane 3), or incubated with ribavirin in gluc
  media for 2 h (lane 5). After treatment, cells were scraped in buffer 
A containing 0.1% Triton X-100 and were either NEM treated as above to abolish RanGAP and GEF activity (lanes 1–7) or mock treated 
(lane 8). The unlabeled nucleotides added upon cellular lysis were 2 mM GDP- S (lanes 1–5 and 8), GMP-PNP (lane 6), or GTP (lane 7). After 
NEM or mock treatment, RanGTP was isolated from the soluble cytosolic extract by incubation with GST–RanBD and glutathione-agarose. 
Bound protein was solubilized with SDS-PAGE sample buffer, separated on a 15% gel, transferred to nitrocellulose, and immunoblotted with 
an anti-Ran antibody. Note in particular the absence of detectable RanGTP in cells treated with 2-deoxyglucose/azide (lane 3). (D) Immunoblot 
of total cell extracts shows that the amount of total cellular Ran doesn’t change after these treatments. 
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To confirm that a 20-min incubation with 100 mM
NEM inhibits RanGAP and RanGEF activity sufficiently
in cellular extracts such that RanGTP can be quantitatively
recovered in a pulldown with GST–RanBD, [
 
 
 
-
 
32
 
P]GTP-
or [
 
 
 
-
 
32
 
P]GTP-loaded recombinant Ran was added (to-
gether with NEM) to the lysate immediately upon cell
lysis. As a control for the efficiency of recovery of radio-
labeled RanGTP in the absence of the RanGAP and
RanGEF and endogenous unlabeled RanGTP, a BSA solu-
tion was substituted for cellular extract in some samples. As
shown in Fig. 4, A and B, exogenously added [
 
32
 
P]GTP–
Ran can be recovered by the GST–RanBD from cellular
extracts to the same extent as from a BSA solution with,
but not without, NEM treatment of the extract. A negligi-
ble amount of counts was recovered when GST was substi-
tuted for GST–RanBD. As the radiolabeled RanGTP and
NEM were added together immediately upon cell lysis,
these experiments confirmed that this NEM treatment was
capable of preserving RanGTP present in a cellular extract
after cell lysis.
Shown in Fig. 4 C are the amounts of free RanGTP that
can be isolated from extracts of 2-deoxyglucose/azide- and
ribavirin-treated cells. In untreated cells (lane 1), or cells
incubated in gluc
 
 
 
 media for 1 (lane 2) or 2 h (lane 4),
substantial amounts of free RanGTP could be detected in
the GST–RanBD eluate. That NEM treatment is inhibit-
ing the GAP and GEF activity normally present in cellular
extracts can be seen by comparing the amount of Ran in
lane 1 (NEM-inactivated extract from control cells) with
the amount in lane 8 (mock-inactivated extract from con-
trol cells). The decreased RanGTP in lane 8 is presumably
due to GAP or GEF activity in the lysate. In all of these
samples except those in lanes 6 and 7 (and in the experi-
ment shown in Fig. 3), an excess of GDP
 
 
 
S (together with
the NEM) was added upon cell lysis. This was to ensure
that if any nucleotide exchange occurred on Ran before in-
activation of the RanGEF, the Ran would be loaded into
the GDP- and not the GTP-bound form, thus avoiding an
overestimation of the cellular RanGTP. When GTP (lane
7) or GMP-PNP (lane 6) were added in place of GDP
 
 
 
S, a
slight increase in isolated RanGTP could be detected, indi-
cating a slight amount of residual RanGEF activity that
was not detected in the experiment shown in Fig. 3. We
concluded that this NEM treatment was inhibiting the
GAP and GEF activity in the lysate as much as was techni-
cally possible, and that this treatment would allow us to
obtain a good estimate of the relative levels of free
RanGTP present in the cell after these various treatments.
The most significant result from this experiment was that
after 1 h of treatment with 2-deoxyglucose/azide, no
RanGTP could be detected in the lysate (compare lane 3
with lanes 1 and 2). Immunoblotting with an anti-Ran an-
tibody of the different extracts before incubation with the
RanBD indicated that the total cellular Ran content was
unchanged after these different treatments (Fig. 4 D), indi-
cating that only free RanGTP was lost, and not total Ran.
Ribavirin treatment (2 h) resulted in a slight decrease in
the available RanGTP (Fig. 4 C, compare lanes 4 and 5),
but the amount remaining was still significantly higher
than in the 2-deoxyglucose/azide-treated cells.
 
Buildup of Kap-
 
 
 
 in the nucleus of
2-deoxyglucose/azide-treated cells occurs 
concomitantly with a loss of RanGTP
 
Now that we had established that 2-deoxyglucose/azide
treatment for 1 h drops the available RanGTP to undetect-
able levels, we wanted to see whether the disappearance of
RanGTP upon 2-deoxyglucose/azide treatment correlated
in time with the cessation of transport. A time course ex-
amination of 2-deoxyglucose/azide treatment was per-
formed, and at every time point, cells were either fixed and
the localization of Kap-
 
 
 
 was determined by immunofluo-
rescence microscopy, or lysed and measured for available
RanGTP as described above (Fig. 5). We found that the
amount of available RanGTP in the lysate detectable in
our assay dropped very quickly after the addition of
2-deoxyglucose/azide, with a noticeable decrease in available
RanGTP observable just 30 s after addition. The amount
of available RanGTP continued to decrease after 45 s and 2
min of treatment, and after 5 min of treatment, available
RanGTP was no longer detectable. Available RanGTP re-
mained undetectable by this assay from 5 min to 1 h of
treatment. Buildup of Kap-
 
 
 
 in the nucleus was slightly
apparent after 2 min of treatment, more noticeable at 5
min, and very striking after 10 min, with the cells at this
time point exhibiting some heterogeneity in their amount
of Kap-
 
 
 
 nuclear accumulation. Between 10 min and 1 h
of treatment, there was a decrease in this heterogeneity,
with every cell exhibiting very strong Kap-
 
 
 
 nuclear accu-
mulation after 1 h of treatment.
We also found that the reappearance of RanGTP during
recovery from 2-deoxyglucose/azide treatment occurs con-
comitantly with the movement of Kap-
 
 
 
 out of the nucleus
(Fig. 5 B). Deoxyglucose/azide-treated cells allowed to re-
cover for only 1 min in gluc
 
 
 
 media had a detectable
amount of RanGTP and decreased Kap-
 
 
 
 signal in the nu-
cleus. After 10 min of recovery, the concentration of avail-
able RanGTP was almost back to normal as was the cellular
distribution of Kap-
 
 
 
. Thus, the decrease in free RanGTP
precedes the nuclear accumulation of Kap-
 
 
 
 upon treatment
with 2-deoxyglucose/azide, and the reappearance of free
RanGTP during recovery from this treatment coincides with
movement of Kap-  out of the nucleus.
The effects on free (rather than total) GTP levels by 
2-deoxyglucose/azide and ribavirin treatment
As inactivation of the RanGEF resulting in a lack of RanGTP
is known to result in a nuclear buildup of Kap-  (Tachibana
et al., 2000), we reasoned that the lack of RanGTP in 2-deoxy-
glucose/azide-treated cells (Figs. 4 and 5) was likely to be trig-
gering the same event. What was unclear from our data how-
ever, is why free RanGTP was absent in the 2-deoxyglucose/
azide-treated cells (Fig. 4), when these cells had significantly
higher levels of GTP than ribavirin-treated cells (Table I). We
decided to measure the free rather than the total GTP concen-
tration, reasoning that it was the pool of free GTP rather than
total GTP (free plus protein bound) that would be used to
load Ran to form RanGTP.
To measure the concentration of free GTP, immediately
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passed the supernatant through a filter (10 kD mol wt cut-
off) to remove free nucleotide from that which was bound
to proteins over 10 kD. This filtered extract was then mea-
sured for its GTP and ATP content. We found that the
ATP from control cells that passed through the filter (i.e.,
free ATP) (4.48 nmoles/10
6 cells) was 55% of the cellular
total (8.22 nmoles/10
6 cells) (Table II). Free GTP from
control cells (0.93 nmoles/10
6 cells) represented 36% of the
total (2.58 nmoles/10
6 cells). Notably, the amount of free
GTP present in control cells (0.93 nmoles/10
6 cells) de-
creases after ribavirin treatment to 0.3 nmoles/10
6 cells, but
drops even further to an undetectable level after 2-deoxy-
glucose/azide treatment ( 0.1 nmoles/10
6 cells). Note that
the latter value is actually an overestimation, as free GTP
and ATP in extracts from 2-deoxyglucose/azide-treated cells
were undetectable by FPLC and the values in Table II
therefore represent the minimum we can detect by FPLC
rather than the actual nucleotide present in the samples.
Even when twice the normal sample volume (containing
free nucleotide) was loaded from 2-deoxyglucose/azide-
treated cells, there still was not a perceptible peak corre-
sponding to GTP or ATP on the FPLC trace (unpublished
data). Thus 2-deoxyglucose/azide treatment has a greater ef-
fect on free GTP levels than GTP depletion with ribavirin.
We believe that the absence of free GTP in the 2-deoxyglu-
cose/azide-treated cells inhibits loading of Ran with GTP,
and this lack of free GTP is likely to be the causative factor
in the inhibition of Ran-dependent nuclear transport by
ATP depletion.
Entry of Kap-  into the nucleus is also inhibited by 
2-deoxyglucose/azide
We had one final question concerning the nuclear accumu-
lation of Kap-  seen upon 2-deoxyglucose/azide treatment
Figure 5. A time course of 2-deoxyglucose/azide 
treatment and recovery comparing the availability 
of RanGTP with the nuclear buildup of Kap- . 
For each time point in A and B, the cellular 
localization of Kap-  as determined by indirect 
immunofluorescence microscopy (performed as in 
Fig. 2) was compared with the RanGTP from NEM-
treated cellular extracts that bound to the RanBD 
(performed as in Fig. 4 C, lanes 2 and 3, arrow). 
(A) HeLa cells were incubated for the indicated 
time at 37 C in gluc
  media containing 2-deoxy-
glucose/azide. (B) After treatment in 2-deoxyglucose/
azide for 1 h, the cells were washed once in 
prewarmed gluc
  media, and then transferred to 
prewarmed gluc
  media and incubated at 37 C for 
the indicated time. To emphasize the heterogeneity 
in Kap-  nuclear accumulation at longer time 
points, the same relatively short camera exposure 
time was used for all of these micrographs.
Table II. Measurement of free nucleotides in HeLa cells after various treatments
Free ATP Total ATP (from Table I) Free GTP Total GTP (from Table I)
Glucose
  media, 1 h 4.48   0.27 8.22   0.75 0.93   0.22 2.58   0.23
2-deoxyglucose   sodium azide, 1 h  0.1
a 3.27   0.60  0.1
a 1.85   0.29
Ribavirin, 2 h 5.93   1.07 8.42   0.43 0.30   0.04 0.87   0.01
Values are expressed as nmoles nucleotide/10
6 cells. Free nucleotide was separated from the total cellular lysate by filtration as described in the Materials
and methods. Values for free ATP and GTP represent the mean   SD of three independent experiments; the values for total ATP and GTP were taken from
separate experiments summarized in Table I.
aBoth the free ATP and GTP from the cells treated with 2-deoxyglucose and sodium azide were essentially undetectable by FPLC, and thus below our low-
est standards. The values given for these two measurements therefore indicate the amount of our lowest FPLC standards rather than the exact concentration
of nucleotide.970 The Journal of Cell Biology | Volume 157, Number 6, 2002
(Figs. 2 and 5). For Kap-  to accumulate in the nucleus, its
nuclear import must continue after its export has stopped. If
a lack of RanGTP is solely responsible for this nuclear accu-
mulation of Kap- , then CAS-mediated export of Kap- 
must be more sensitive to RanGTP depletion than the im-
port of the NLS cargo–Kap- –Kap- 1 complex, and there
is some evidence that this is in fact the case (Izaurralde et al.,
1997; see Discussion). An alternate explanation is that Kap- 
can somehow enter, but not exit, nuclei in an energy-inde-
pendent fashion. There has been one report linking Kap- 
to the ubiquitin/proteosome system (Tabb et al., 2000), and
other reports that the yeast Kap-  (Srp1) interacts with a
yeast NPC protein (Nup2) that is mobile in the NPC (Be-
langer et al., 1994; Hood et al., 2000; Solsbacher et al.,
2000; Dilworth et al., 2001). Because of these reports, we
wanted to determine whether Kap-  can possibly enter the
nucleus under conditions of energy depletion when the im-
port of cNLS cargo is inhibited.
To test whether Kap-  can still enter the nucleus of en-
ergy-depleted cells, we pretreated HeLa cells with either nor-
mal media or gluc
  media containing 2-deoxyglucose/azide
for 20 min. We then microinjected either FITC–Kap-  or
TRITC–NLS-BSA (as a control) into the cytoplasm. After
incubation for 30 min in the treatment media, we fixed and
observed the cells to see whether these two reporters had en-
tered the nuclear interior (Fig. 6). In untreated cells, cyto-
plasmically injected FITC–Kap-  could be detected after 30
min in the nuclear interior in addition to the cytoplasm; the
FITC–Kap-  is presumably cycling between the cytoplasm
and nucleus like the endogenous unlabeled Kap- . TRITC–
NLS-BSA in control cells was exclusively nuclear at this time
as in the experiment shown in Fig. 1. In contrast, in cells
treated with 2-deoxyglucose/azide, FITC–Kap-  as well as
TRITC–NLS-BSA remained exclusively cytoplasmic. This
result shows that import of Kap-  into the nucleus is inhib-
ited in energy-depleted cells.
Discussion
In this study, we examined the mechanism of how cellular
ATP depletion inhibits Ran-dependent nuclear transport.
First we found that ATP depletion with 2-deoxyglucose/
azide inhibited both Ran-dependent import of cNLS cargo
and Ran-dependent export of leucine-rich NES cargo but
Figure 6. The entry of microinjected FITC–Kap-  into 
the nucleus is inhibited by 2-deoxyglucose/azide 
treatment. HeLa cells were incubated in either normal 
media or gluc
  media containing 2-deoxyglucose/azide 
for 20 min. They were then microinjected into the 
cytoplasm with either (A) TRITC–NLS-BSA (9.1 mg/ml) 
and a FITC 70-kD dextran marker (6.7 mg/ml) or (B) 
FITC–Kap-  (1.7 mg/ml) and a Cascade blue 70-kD 
dextran marker (0.9 mg/ml). After injection (which took 
 10 min), the cells were incubated for an additional 30 
min in the treatment media before fixation.ATP depletion and nuclear transport | Schwoebel et al. 971
that GTP depletion with ribavirin inhibited neither (Fig.
1). 2-deoxyglucose/azide (unlike ribavirin) treatment also
caused an accumulation of Kap-  inside the nucleus (Fig.
2). Measurement of the total nucleotide levels revealed that
after 2-deoxyglucose/azide treatment, the total ATP content
decreased to 40% of control, whereas the GTP content only
decreased to 72% of control (Table I). In contrast, after ri-
bavirin treatment, the total ATP concentration was un-
changed (101% of control), but the total GTP content de-
creased to 36% of control. Because ribavirin-treated cells
remain transport competent whereas 2-deoxyglucose/azide-
treated cells do not, these nucleotide measurements did not
support our original hypothesis that it is a drop in total GTP
levels upon ATP depletion that inhibits transport.
In further experiments, however, we found that 2-deoxy-
glucose/azide treatment causes the amount of RanGTP avail-
able for binding to a GST–RanBD construct to drop to un-
detectable levels (Fig. 4). We further found that this decrease
in RanGTP precedes the nuclear accumulation of Kap- 
(Fig. 5). Finally, we found that 2-deoxyglucose/azide treat-
ment resulted in the level of free (unlike total) GTP to drop
to undetectable levels. Ribavirin treatment caused a decrease
in free GTP to 32% of control (Table II), but this value is
substantially higher than the free GTP concentration in
2-deoxyglucose/azide-treated cells. Treatment with ribavirin
for longer than 2 h was not tested, but because we did detect
a decrease in free RanGTP after 2 h of ribavirin treatment
(Fig. 4), it is possible that longer treatment times might
eventually cause the RanGTP concentration to drop to a
point where Ran-dependent nuclear transport is inhibited.
Because of these results, we believe it likely that the inhibi-
tion of Ran-dependent nuclear transport seen with ATP de-
pletion in fact results from a loss of free GTP needed to pro-
duce RanGTP, rather than by an ATP-dependent step in
nuclear transport. Because we also found that free ATP also
drops to undetectable levels upon 2-deoxyglucose/azide
treatment, it remains formally possible that free ATP (in ad-
dition to free GTP) is also required for these transport path-
ways in vivo. However, because all of the previously pub-
lished in vitro data is completely consistent with an essential
requirement for GTP to make RanGTP, and shows no de-
tectable requirement for ATP or ADP, we favor the interpre-
tation that it is the loss of free GTP rather than free ATP
upon 2-deoxyglucose/azide treatment that is the critical
event (Schwoebel et al., 1998; Englmeier et al., 1999).
In addition to the experiments shown, we did a num-
ber of experiments to rule out other explanations of why
2-deoxyglucose/azide inhibits Ran-dependent nuclear trans-
port. First, we considered the possibility that sodium azide
was having a direct effect on transport rather than inhibit-
ing it by lowering nucleotide levels. Azide inhibits oxidative
phosphorylation by binding to cytochrome oxidase in the
mitochondria, however azide also binds and inhibits other
metal-containing proteins such as HRP (Holzwarth et al.,
1988). We found, however, that the direct addition of so-
dium azide at millimolar concentrations to digitonin-per-
meabilized cells did not have the slightest effect on either
the in vitro import of TRITC–NLS-BSA or the in vitro ex-
port of TRITC–NES-BSA (unpublished data). Further-
more, we found that substitution of oligomycin, another
inhibitor of oxidative phosphorylation that works by a dif-
ferent mechanism, gave identical results to sodium azide in
terms of Kap-  nuclear buildup (unpublished data). We
also found that cytoplasmic microinjection of apyrase, an
enzyme that cleaves any tri- or diphosphate nucleotide to its
monophosphate derivative, resulted in identical nuclear ac-
cumulation of Kap-  (unpublished data).
We considered the possibility that ATP depletion might
be inhibiting some ATP-dependent posttranslational modi-
fication of a protein involved in nuclear transport, such as
an NPC protein or one of the transport factors. With re-
gard to this, we found that neither the RanGEF or Ran-
GAP activities in lysates from 2-deoxyglucose/azide-treated
cells were altered when compared with extracts from con-
trol or ribavirin-treated cells (unpublished data). It is also
possible that the export of large ribonucleoprotein com-
plexes might require an additional energy source, unlike
the export of smaller substrates, to power an ATP-depen-
dent helicase for example (Gatfield et al., 2001). We rea-
soned that the absence of ATP might “jam” the NPC with
partially translocated RNPs, preventing the movement of
smaller transport complexes. We found, however, that in-
hibition of RNA synthesis with actinomycin D for several
hours before 2-deoxyglucose/azide treatment had no effect
on the subsequent nuclear accumulation of Kap-  (unpub-
lished data). We also found that with regard to potential
jamming of the NPC, 2-deoxyglucose/azide treatment did
not prevent the diffusion of a 25-kD protein through the
NPC (unpublished data).
In summary, our results support the conclusion that inhi-
bition of Ran-dependent transport by ATP depletion does
not result from inhibition of an ATP-dependent step in these
transport pathways. It should be noted that the results re-
ported here do not rule out the possibility that other trans-
port pathways, or the Kap- 1 and Crm1 pathways when
transporting much larger cargo than those tested here, might
require additional energy sources to facilitate movement
across the NPC. However, we believe the inhibition of the
pathways studied here directly results from a lack of RanGTP
and this lack is caused by a shortage of free GTP needed for
the loading of nuclear RanGDP. It is striking that the level of
free GTP becomes undetectable after 2-deoxyglucose/azide
treatment when the pool of total GTP is still 72% of normal
(Table II). One reason for this rapid loss of free GTP seen
upon ATP depletion is probably the requirement for ATP in
the sequential phosphorylation of GMP to form GDP and
GTP (Zalkin and Dixon, 1992). Thus, an absence of ATP
should completely inhibit the de novo synthesis of GTP. An-
other key player likely to be involved in regulating relative
NTP levels is nucleoside diphosphokinase, which transfers
the terminal phosphate from any NTP to the terminus of any
NDP (Veron et al., 1994). This could have the effect of de-
pleting GTP pools in parallel with ATP pools in cells under
2-deoxyglucose/azide treatment. Contributing to the rapid
loss of free GTP upon ATP depletion is probably the pres-
ence of many cellular ATP-using proteins that can also use
GTP, e.g., hexokinase (Ferguson et al., 1986). Under normal
conditions, these proteins use the most available NTP, which
is ATP, but in the absence of free ATP, they can use GTP in-
stead, which would rapidly deplete this pool as well.972 The Journal of Cell Biology | Volume 157, Number 6, 2002
If the nuclear accumulation of Kap-  upon energy deple-
tion is caused by a lack of RanGTP, this would have to mean
that its CAS-mediated export is more sensitive to RanGTP
depletion than its Kap- 1–mediated import. Evidence that
Kap-  export is in fact more sensitive to RanGTP depletion
than cNLS import was shown by microinjecting radiolabeled
proteins or RNAs into Xenopus oocytes followed by hand dis-
section and observing their transport under conditions where
nuclear RanGTP is depleted (Izaurralde et al., 1997). This
study found that the nuclear export of Kap-  is almost to-
tally inhibited after nuclear injection of 10  M RanGAP
(Rna1), but that the import of a cNLS-containing cargo
(CBP80) is only slightly reduced by this GAP concentration
and requires the nuclear injection of 40  M RanGAP for to-
tal inhibition. Thus, these findings support our conclusion
that it is the loss of RanGTP that inhibits Ran-dependent
nuclear import and export upon ATP depletion rather than
the inhibition of some ATP-dependent event.
Materials and methods
Materials
Ribavirin was from Sigma-Aldrich. The following antibodies were used:
anti-Ran monoclonal antibody from Transduction Laboratories, anti-Ran
GAP monoclonal antibody 19C7 ascites fluid (Matunis et al., 1996) do-
nated by M. Matunis (Johns Hopkins University, Baltimore, MD), anti–Kap- 
(pendulin) antisera donated by M. Waterman (University of California,
Irvine, CA), anti–Kap- 1 monoclonal antibody (Chi et al., 1995) donated
by S. Adams (Northwestern University Medical School, Chicago, IL), and
anti-RCC1 rabbit antibody (Schwoebel et al., 1998). Rhodamine-conju-
gated secondary antibodies against mouse and rabbit IgG were from
Jackson ImmunoResearch Laboratories. TRITC–NLS-BSA was prepared as
previously described (Moore and Blobel, 1992). TRITC–NES-BSA was pre-
pared in the same manner, substituting peptides (CLPPLERLTL) containing
the Rev NES (in bold) (Fischer et al., 1995; Wen et al., 1995). Fluorescein-
and Cascade blue–labeled 70-kD dextrans were from Molecular Probes.
FITC–Kap-  was prepared by coupling His–Kap- 2 (Schwoebel et al.,
1998) with a 1:2 molar ratio of fluorescein–5-isothiocyanate (Molecular
Probes) according to the manufacturer’s instructions. After coupling, FITC–
Kap-  was passed over a Nap-5 column equilibrated in 20 mM Hepes-
KOH, pH 7.3, 100 mM potassium acetate, 2 mM DTT, snap frozen, and
stored at  80 C in single use aliquots. We found that labeling did not af-
fect the ability of Kap-  to support cNLS-mediated import in permeabi-
lized cells (unpublished data).
Cell culture and treatments
For energy depletion studies, HeLa cells were washed with PBS, and incu-
bated in glucose-free DME (catalog no. 11966–025; GIBCO BRL) contain-
ing penicillin (100 U/ml), streptomycin sulfate (100  g/ml), Hepes (10
mM, pH 7.3), and 10% FCS (hereafter referred to as gluc
  media). Where
indicated, cells were incubated in gluc
  media containing either 10 mM
sodium azide and 6 mM 2-deoxy-D-glucose, or 100  M ribavirin for the
times indicated in the figure legends. For microinjection, coverslips were
rinsed once in PBS, once in gluc
  media, and incubated with gluc
  media
containing 10 mM sodium azide and 6 mM 2-deoxyglucose for 20 min or
gluc
  media containing 100  m ribavirin for 90 min at 37 C before micro-
injection. Microinjection was for  10 min at room temperature (RT) in
treatment media, and microinjected cells were then incubated for an addi-
tional 30 min at 37 C before fixation.
Immunofluorescence microscopy
Cells after treatment were placed on ice, washed with ice cold PBS, fixed
for 20 min on ice in 3% formaldehyde (diluted from a methanol-free stock)
in PBS, rinsed twice with PBS, and permeabilized with 0.1% Triton in PBS
for 20 min on ice. Cells were blocked with 10% donkey serum in PBS for
30 min at 37 C, washed two times with PBS, and incubated with primary
antibody diluted in blocking serum for 1 h at RT. After washing, cells were
incubated with a labeled second antibody in blocking solution for 1 h at
RT. After washing, coverslips were mounted and observed as previously
described (Schwoebel et al., 1998).
Nucleotide isolation and quantitation
Total nucleotide.  After treatment, cells were washed with PBS, trypsinized,
and the cells were resuspended in ice cold PBS and centrifuged for 5 min
at 200 g, 4 C. Cells were resuspended in cold PBS, counted, centrifuged
for 5 min at 200 g, 4 C, and resuspended in 0.7 M HClO4 (100  l/10
6
cells). Cells were vortexed for 30 s, centrifuged at 3,000 g for 20 min at
4 C, and the supernatants were neutralized with solid KHCO3 (10 mg/10
6
cells) (Kremmer et al., 1989). The precipitates were removed by microcen-
trifugation twice for 10 min at 4 C each time, and the supernatants were
aliquoted and snap frozen in liquid N2. Aliquots of these supernatants
(each representing 6.5   10
5 cells) were used for the measurement of nu-
cleotides. Nucleotides were separated by FPLC and individual nucleotide
levels were quantitated by measurement of peak heights (Abs UV254) and
comparison to standard curves. GTP and ATP were separated on a Mono-Q
column with a gradient of 2–55% B (A   H2O; B   1 M ammonium phos-
phate, pH 7.0; Kremmer et al., 1989). With this protocol, ATP elutes at
48.5% B, and GTP at 52% B. GDP and ADP were separated on a Source
15Q column with a gradient of 0–60% B (A   7 mM KH2PO4, pH 4.5; B  
500 mM KH2PO4, 100 mM KCl, pH 5.0; Hartwick and Brown, 1975). With
this protocol, GDP elutes at 23.5% B, and ADP elutes at 26% B.
Free nucleotide.  After treatment, cells were washed with cold PBS and
scraped in cold buffer A (20 mM Hepes, pH 7.3, 120 mM NaCl, 2 mM
magnesium acetate, 1 mM DTT). The scrapes from three 100-mm culture
dishes were pooled and sonicated. An aliquot of the lysate was snap fro-
zen in liquid nitrogen and saved for Bradford analysis. The cell number
was calculated from the protein values compared with the previously de-
termined protein content of a known number of HeLa cells. The remaining
lysate was centrifuged in a Microcon centrifugal filter device with a 10,000
mol wt cutoff (Millipore) at 12,000 g for 10 min at 4 C. The resulting fil-
trate was snap frozen in liquid nitrogen. The GTP and ATP content of the
filtrate was measured by FPLC as described above.
NEM treatment and measurement of free RanGTP
Preparation of extracts and initial NEM experiments.  All steps including in-
cubation with NEM were performed on ice in a cold room using ice cold
solutions unless otherwise stated. HeLa cells were washed once with PBS,
and then the cells were scraped using a rubber policeman into buffer A
containing 0.1% Triton X-100. The lysate was vortexed for 15 s and NEM at
different concentrations was added to aliquots of the lysate. Aliquots were
removed at different time points and a twofold molar excess of DTT over
the NEM in that particular sample was added to quench the NEM activity.
RanGAP and RanGEF assays.  Before assay, each NEM-treated lysate
(quenched with DTT) to be assayed for GAP or GEF activity was gel filtered
on a Nap-5 column equilibrated in 20 mM Hepes, pH 7.3, 120 mM NaCl,
5 mM magnesium acetate, 0.05% Tween, and 5 mM DTT. Human recom-
binant untagged Ran (3  g) was loaded with radiolabeled nucleotide for
2 h on ice in 20 mM Hepes, pH 7.3, 120 mM potassium acetate, 1 mM
DTT, 10 mM EDTA, 1 mg/ml BSA, and either 5.5 pmol of 9,000 Ci/mmol
[ -
32P]GTP (NEN Life Science Products) or 3.3 pmol of [ -
32P]GDP pre-
pared as previously described (Schwoebel et al., 1998). The loading reac-
tion was quenched by the addition of MgCl2 to 40 mM. The loaded Ran
was microfuged for 10 min at 4 C and exchanged into buffer B (20 mM
Hepes, pH 7.3, 120 mM potassium acetate, 5 mm MgCl2, 1 mM DTT) by
passage over a NAP-5 desalting column. For the GAP assay, 40,000 CPM
of GTP loaded Ran was added to each sample, vortexed, and placed at
30 C. The reaction was stopped after 15 min by the addition of 5 ml ice
cold buffer B. The sample was vacuum filtered onto 0.45- m nitrocellu-
lose filters (Schleicher & Schuell), and the filters were washed with 12 ml
cold buffer B. The filters were air dried, placed in scintillation fluid, and
counted. The GEF assay was performed in the same manner using 20,000
CPM of [ -
32P] GDP-loaded Ran per sample.
RanBD1 pulldowns of Ran[ -
32P]GTP and Ran[ -
32P]GTP.  Human recom-
binant untagged Ran (3  g) was loaded with radiolabeled nucleotide for
2 h on ice in 20 mM Hepes, pH 7.3, 120 mM potassium acetate, 1 mM
DTT, 10 mM EDTA, 1 mg/ml BSA, and either 34 pmol of 9,000 Ci/mmol
[ -
32P]GTP or 38.8 pmol of 3,000 Ci/mmol [ -
32P]GTP (both from NEN
Life Science Products). The loading reaction was quenched by the addition
of MgCl2 to 40 mM, and the loaded Ran was exchanged into buffer B by pas-
sage over a NAP-5 column. HeLa cells grown to 70% confluence in 100-
mM dishes were placed on ice in the cold room, washed in PBS, drained,
and scraped in buffer B containing 0.1% Tween-20, 2.8 mM GDP- S, and
140 mM NEM (except mock-treated samples, which contained 280 mM
DTT). Aliquots of the radiolabeled Ran were added immediately to these
cell lysates. In some samples, BSA (10 mg/ml in buffer B) was used in place
of cellular extract. After dilution, the final concentrations were 100 mM
NEM and 2 mM nucleotide. The samples were incubated on ice for 20
min, vortexed, and centrifuged at 13,000 g for 10 min at 4 C. The superna-ATP depletion and nuclear transport | Schwoebel et al. 973
tants were brought to 200 mM DTT (from a 2 M stock) and applied to a
NAP-5 column equilibrated in buffer A. GST–RanBD or GST was added to
the NAP-5 eluates and the samples were rotated end over end for 30 min
at 4 C. Glutathione-agarose beads were added and the incubation contin-
ued for an additional 30 min at 4 C. Approximately 7  g of GST–RanBD or
GST and 40  l of a 20% slurry of glutathione-agarose beads were added
per milligram of cellular extract. After incubation, the beads were sedi-
mented by centrifugation at 1,000 g for 3 min at 4 C. The supernatants
were discarded and the pellets washed four times in buffer A. Beads were
resuspended in SDS-PAGE sample buffer and aliquots of the resulting su-
pernatant were placed in scintillation fluid and counted.
RanBD1 pulldowns of RanGTP from treated cells.  After receiving the indi-
cated treatment, HeLa cells grown to 70% confluence in 100-mM dishes
were placed on ice in the cold room, washed in PBS, drained, and scraped
in buffer B containing 0.1% Tween-20, 2.8 mM nucleotide (GDP- S ex-
cept where indicated), and 140 mM NEM (except mock-treated samples,
which contained 280 mM DTT). After dilution, the final concentrations
were 100 mM NEM and 2 mM nucleotide. After incubation for 20 min on
ice, the samples were quenched with DTT and processed for isolation of
free RanGTP with the GST–RanBD and glutathione-agarose as described
above. Beads were resuspended in SDS-PAGE sample buffer, and after
SDS-PAGE, the samples were transferred to nitrocellulose and immuno-
blotted with an anti-Ran antibody.
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